Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced promising new data from its Phase 2 trial of ATH434 in Multiple ...

In other recent news, Alterity Therapeutics Limited has secured A$40 million in funding to advance the development of its lead drug candidate, ATH434, for Multiple System Atrophy (MSA).

In other recent news, Alterity Therapeutics Limited has secured A$40 million in funding to advance the development of its lead drug candidate, ATH434, aimed at treating Multiple System Atrophy (MSA).

In other recent news, Alterity Therapeutics Limited has secured A$40 million in funding to advance the development of its lead drug candidate, ATH434, for Multiple System Atrophy (MSA). This funding ...

In other recent news, Alterity Therapeutics Limited has secured A$40 million in funding to advance the development of its lead drug candidate, ATH434, aimed at treating Multiple System Atrophy (MSA).